May 10 Eli Lilly and Co said it will
stop developing its experimental cancer drug after a late-stage
trial failed to show a statistically significant increase in
patients' disease-free survival.
The drug, enzastaurin, was being tested in lymphoma patients
who were at high risk of relapse following a chemotherapy
treatment. Lymphoma is a cancer of the lymphatic system.
The decision to stop the drug's development will result in a
second-quarter charge of about $30 million but the company's
2013 forecast remained unchanged, Lilly said in a statement.